The BY-CD28/CTLA-4 co-stimulatory pathway has a critical role in regulating T cell activation, and manipulation of this key immunoregulatory pathway has great therapeutic potential. We have cloned a novel murine gene that is a third member of the CD28/CTLA4 gene family and is the murine homologue of the recently described human ICOS (Inducible Co-stimulatory) gene. ICOS is expressed on activated murine T cells and expression as restricted to T cells, similarly to CD28 and CTLA4. In humans, ICOS functions as a receptor for co-stimulatory signals leading to T cell proliferation and production of IL-4 and IL-10, but not IL-2. The relationships of ICOS with the receptors and ligands in the B7-CD28/CTLA-4 pathway need to be define. It is not yet known whether ICOS binds B7 co-stimulators or if ICOS binds to an as yet to be identified counter-receptor in a parallel pathway. It is also not clear when ICOS co-stimulation is needed during immune response. Because ICOS stimulates IL-4 and super-induces IL-10 production, ICOS co-stimulation may have an important role in T cell differentiation and the generation of regulatory T cells. Therefore, manipulation of ICOS signaling may have therapeutic potential. The goal of this research project is to elucidate the role of ICOS co-stimulation in T cell activation, differentiation, and tumor immunity. We have developed a murine ICOS fusion protein that enables us to analyze the function of ICOS on naive and previously activated T cells to characterize the expression and function of ICOS counter-receptor, and to analyze the function of ICOS interactions with the B7/CD28 pathway. In this project, we will characterize how ICOS functions as a receptor for co-stimulator signals from antigen presenting cells and how ICOS regulates T cell proliferation and differentiation. We will examine the role of ICOS co-stimulation in the generation of an effective anti-tumor response in vivo using the EL4 tumor model since the role of IL-4 and IL-10 in suppression of effective tumor immunity has been well defined in this model. ICOS function may deviate the immune response away from a protective cytolytic anti-tumor response and towards a suppressive anti-tumor Th2 response. To understand the role of ICOS in the T cell response and in anti-tumor immunity, I propose to:
SPECIFIC AIM 1. To examine the role of ICOS in T cell activation and differentiations.
SPECIFIC AIM 2. To examine the expression the expression of ICOS counter-receptor on APC and characterize its molecular structure.
SPECIFIC AIM 3. To examine how blocking ICOS signals affect the immune response to murine tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084500-03
Application #
6475869
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Hecht, Toby T
Project Start
1999-12-13
Project End
2004-11-30
Budget Start
2002-01-30
Budget End
2002-11-30
Support Year
3
Fiscal Year
2002
Total Cost
$230,542
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Shaw, Michael H; Freeman, Gordon J; Scott, Mark F et al. (2006) Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. J Immunol 176:7263-71
Keir, Mary E; Liang, Spencer C; Guleria, Indira et al. (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203:883-95
Hirano, Naoto; Butler, Marcus O; Xia, Zhinan et al. (2006) Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107:1528-36
Keir, Mary E; Latchman, Yvette E; Freeman, Gordon J et al. (2005) Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol 175:7372-9
Stock, Philippe; Akbari, Omid; Berry, Gerald et al. (2004) Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nat Immunol 5:1149-56
Herman, Ann E; Freeman, Gordon J; Mathis, Diane et al. (2004) CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 199:1479-89
Cai, Guifang; Karni, Arnon; Oliveira, Enedina M L et al. (2004) PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol 230:89-98
Liang, Spencer C; Latchman, Yvette E; Buhlmann, Janet E et al. (2003) Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33:2706-16
Brown, Julia A; Dorfman, David M; Ma, Feng-Rong et al. (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170:1257-66
Rodig, Nancy; Ryan, Timothy; Allen, Jessica A et al. (2003) Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 33:3117-26

Showing the most recent 10 out of 19 publications